WAVE Life Sciences (WVE)
(Real Time Quote from BATS)
$6.29 USD
+0.14 (2.28%)
Updated Jul 25, 2024 03:42 PM ET
After-Market: $6.28 -0.01 (-0.16%) 4:06 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.29 USD
+0.14 (2.28%)
Updated Jul 25, 2024 03:42 PM ET
After-Market: $6.28 -0.01 (-0.16%) 4:06 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Zacks News
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 22nd
by Zacks Equity Research
BNFT, EXN, RACE, LLNW, and WVE have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2021.
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -27.87% and -76.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
by Zacks Equity Research
Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Wave Life Sciences (WVE) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Implied Volatility Surging for Wave Life Sciences (WVE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Wendy's Company, WAVE Life Sciences, ADTRAN and USA Truck
by Zacks Equity Research
Zacks.com featured highlights include: Wendy's Company, WAVE Life Sciences, ADTRAN and USA Truck
4 Stocks to Watch for Stellar Earnings Acceleration
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be called earnings acceleration.
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Wave Life Sciences (WVE) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Wave Life Sciences (WVE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Enters Oversold Territory
by Zacks Equity Research
Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.